Background: This study aimed to evaluate the scleral thickness and corneal parameters of patients with systemic lupus erythematosus (SLE).

Methods: Forty-seven eyes of 47 SLE patients and 44 eyes of healthy controls were included in this cross-sectional study. Anterior segment optical coherence tomography (AS-OCT) was used to measure the corneal and scleral thickness. Scleral thickness (ST) was measured based upon the segmentation at 1000 to 5000 μm from the scleral spur. Pentacam HR was used to measure corneal parameters.

Results: There was no statistically significant difference between SLE group and control group according to age and sex (P > .05). The ST measurements at all distances from scleral spur were found to be thicker in patients with SLE (P < .05). Central corneal thickness (CCT), cornea volume (CV), corneal densitometry (CD), and peripheral corneal thickness (PCT) measurements were similar between the groups (P > .05).

Conclusion: ST was thicker in SLE patients compared with healthy controls. AS-OCT seems helpful in selecting optimal sites for pharmaceutical or surgical intervention in SLE patients, since it shows thickness variations in anterior sclera.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402759PMC
http://dx.doi.org/10.1097/MD.0000000000021467DOI Listing

Publication Analysis

Top Keywords

scleral thickness
16
sle patients
12
thickness corneal
8
patients systemic
8
systemic lupus
8
lupus erythematosus
8
healthy controls
8
measure corneal
8
scleral spur
8
patients
6

Similar Publications

Purpose: To investigate the effect of tamsulosin on iris morphology, ciliary muscle thickness (CMT), pupil diameter (PD), and pupil responses to light using anterior segment optical coherence tomography and corneal topography.

Design: Prospective clinical before-and-after study METHODS: The right eyes of 43 patients with newly diagnosed benign prostatic hyperplasia were included in this study. Iris dilator muscle region (DMR) thickness, sphincter muscle region (SMR) thickness, DMR/SMR ratio, PD (scotopic, mesopic and photopic light conditions), CMT1(1 mm posterior to the scleral spur), CMT2(2 mm posterior to the scleral spur), CMT3(3 mm posterior to the scleral spur) and anterior chamber depth(ACD) were measured before and after dilation.

View Article and Find Full Text PDF

Significance: Imaging deep structures with optical coherence tomography (OCT) is difficult in highly scattering biological tissue, such as the sclera. There is a need to visualize the suprachoroidal space and choroid through the sclera to study suprachoroidal drug delivery.

Aim: We aim to develop optical methods to image through the highly scattering sclera with a custom-built OCT system to visualize the suprachoroidal space and drug delivery within.

View Article and Find Full Text PDF

Significance: Imaging deep structures with optical coherence tomography (OCT) is difficult in highly scattering biological tissue, such as the sclera. There is a need to visualize the suprachoroidal space and choroid through the sclera to study suprachoroidal drug delivery.

Aim: We aim to develop optical methods to image through the highly scattering sclera with a custom-built OCT system to visualize the suprachoroidal space and drug delivery within.

View Article and Find Full Text PDF

Purpose: To evaluate tissue glue-assisted plaque placement regarding accuracy, stability, and longer-term outcomes for choroidal tumors with scleral thinning.

Methods: All patients with tissue glue-assisted plaque radiotherapy at a single ocular oncology center were evaluated for patient demographics, tumor features, surgical details, tumor response, and glue-related complications.

Results: There were 13 patients (mean age 72 years) treated with tissue glue-assisted plaque radiotherapy for choroidal melanoma (n=12) or choroidal metastasis (n=1).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!